Keeping Track: Early Thanks Given By ImmunoGen, Provention Bio; More PD-1/L1 Combo Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
The antibody-drug conjugate field is beginning to reach its full potential and big pharma’s attention has been caught.
ImmunoGen’s Elahere, the only antibody-drug conjugate approved for platinum-resistant ovarian cancer in the US, will produce better than anticipated sales for the first quarter of 2023, CEO Mark Enyedy hinted in a recent interview.
At nearly $194,000, the wholesale acquisition cost for Tzield came in above analysts’ $100,000-$115,000 estimates, but payer pushback is not expected as the drug faces no competition.